Sino Biological
VC Fund
Beijing, China
Sino Biological is a VC fund in Beijing focused on Biotechnology and Biopharma. Sino Biological provides a comprehensive set of biological solutions, including contract biological laboratory services and biological reagents, to help their customers accelerate their life science research, drug discovery, and biological product development. Their cutting-edge state-of-the-art platform technologies and proprietary processes allowus to deliver high quality results and products at record speed. Their solutions enable our clients to expand their in-house capacity, accelerate research and development programs, and generate significant cost-savings. Five of the top ten international pharmaceutical companies have taken advantages of their advanced platforms and high-quality services to support their drug discovery and biological R&D programs.Sino Biological is a worldwide leader in recombinant protein and antibody expression using multiple platform technologies, including transient expression in mammalian cells, stable cell line expression, E. coli. fermentation, and baculovirus expression. Sino Biological is also emerging as an antibody service and diagnostic reagent provider through its creative and innovative antibody generation solutions including anti-idiotype antibody generation and IgM purification platforms.They also offer a comprehensive list of biological research solutions including research protein and antibody reagents, purification resins, enzymes, transfection reagents, and diagnostic ELISA kits. They offer high quality reagents at a significant cost saving as compared to prices at US and Europe.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Sino Biological invests in
Stages Sino Biological invests in
Countries Sino Biological invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Liangzhi Xie
|
|||
Rob Burgess
|
|||
Yang Wang
|
|||
Investment Focus
Industry
- Biotechnology 2 (67%)
- Biopharma 1 (33%)
- Life Science 1 (33%)
- Pharmaceutical 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Liangzhi Xie
President and CEO
|
President and CEO | Total investments: 0 | Find email | |
|
Rob Burgess
Chief Business Officer
|
Chief Business Officer | Total investments: 0 | Find email | |
|
Yang Wang
President
|
President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Bio-Link
|
Bio-Link is a drug development company that offers solutions for the life science industry. Bio-Link was founded in 2001 and was headquartered in Shanghai, China. | Series A / Feb 21, 2024 | |
PhaBuilder
|
PhaBuilder is a platform-based & product-based company with advanced technology in synthetic biology, focusing on the transformation and engineering application of halophilic microbes.PhaBuilder was founded in February 2021 by Professor Guoqiang Chen, director of the Center for Synthesis and Systems Biology at Tsinghua University. It mainlyuses the cutting-edge "Next Generation Industrial Biotechnology(NGIB)" to develop and produce a variety of high-value-added products such as PHA - a biodegradable material, ectoine - a pharmaceutical intermediate, and cadaverine - a Nylon 56 precursor. PhaBuilder currently has two PHA plants under construction - the synthetic biology intelligent development plant in Beijing China-Germany Industrial Park and the 10 kt/annum plant in Yichang, Hubei Province. It also plans to build up 3-5 large-scale production bases throughout China within five years. At present, PhaBuilder has completed two rounds of financing, raising around 300 million yuan in total. The investors include Sequoia Capital, China State-owned Enterprise Mixed Ownership Reform Fund, and GRC SinoGreen Fund, etc. In the future, PhaBuilder will constantly promote synthetic biotechnology to deeply integrate with people's lives and upgrade the intelligent biological manufacturing industry, in order to achieve PhaBuilder's core mission of "Using microbes to change the world and build a green future". | $53.3M / Series A / Feb 02, 2023 | |
|
PhaBuilder
|
PhaBuilder is a platform-based & product-based company with advanced technology in synthetic biology, focusing on the transformation and engineering application of halophilic microbes.PhaBuilder was founded in February 2021 by Professor Guoqiang Chen, director of the Center for Synthesis and Systems Biology at Tsinghua University. It mainlyuses the cutting-edge "Next Generation Industrial Biotechnology(NGIB)" to develop and produce a variety of high-value-added products such as PHA - a biodegradable material, ectoine - a pharmaceutical intermediate, and cadaverine - a Nylon 56 precursor. PhaBuilder currently has two PHA plants under construction - the synthetic biology intelligent development plant in Beijing China-Germany Industrial Park and the 10 kt/annum plant in Yichang, Hubei Province. It also plans to build up 3-5 large-scale production bases throughout China within five years. At present, PhaBuilder has completed two rounds of financing, raising around 300 million yuan in total. The investors include Sequoia Capital, China State-owned Enterprise Mixed Ownership Reform Fund, and GRC SinoGreen Fund, etc. In the future, PhaBuilder will constantly promote synthetic biotechnology to deeply integrate with people's lives and upgrade the intelligent biological manufacturing industry, in order to achieve PhaBuilder's core mission of "Using microbes to change the world and build a green future". | $13.2M / Series A / Nov 04, 2022 |
Co-Investors
Agricultural Fund of China
1 deal together
Asymchem Laboratories (Tianjin)
1 deal together
Cathay Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Sino Biological invest in?
Sino Biological invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Series A stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sino Biological?
Public channels for Sino Biological include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sino Biological?
The team at Sino Biological includes Liangzhi Xie (President and CEO), Rob Burgess (Chief Business Officer) and Yang Wang (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
